Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 234

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 8
Chunk 234
---
 assets

    62

    1,821

    Total assets
     
    $
    99,632

    $
    159,784

    Liabilities and stockholders' equity

    Current liabilities:

    Accounts payable
     
    $
    1,507

    $
    2,987

    Accrued expenses and other current liabilities

    9,083

    12,486

    Deferred revenue

    3,015

    2,201

    Operating lease liabilities

    2,251

    2,782

    Total current liabilities

    15,856

    20,456

    Operating lease liabilities, net of current portion

    22,958

    17,437

    Deferred revenue, non-current

    3,620

    9,107

    Other long-term liabilities

    —

    43

    Total liabilities

    42,434

    47,043

    Commitments and contingencies (Note 7)

    Stockholders' equity:

    Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 38,339,697 and 38,114,606 shares issued and outstanding at December 31, 2024 and 2023, respectively

    —

    —

    Additional paid-in capital

    484,504

    476,989

    Accumulated other comprehensive gain

    97

    37

    Accumulated deficit

    (427,403
    )

    (364,285
    )

    Total stockholders' equity

    57,198

    112,741

    Total liabilities and stockholders' equity
     
    $
    99,632

    $
    159,784

See accompanying notes to the consolidated financial statements.

89

BOLT BIOTHERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(in thousands, except share and per share amounts) 

    Years Ended December 31,

    2024

    2023

    Collaboration revenue
     
    $
    7,690

    $
    7,876

    Operating expenses:

    Research and development

    57,469

    61,542

    General and